Completed
A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects
NCT01171313
- Conditions
- Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +7 more
- Locations
-
- XenoPort Clinical Site Phoenix, Arizona, United States
- XenoPort Clinical Site Little Rock, Arkansas, United States
- XenoPort Clinical Site Long Beach, California, United States
- XenoPort Clinical Site Sunnyvale, California, United States